AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.14 Million USD | -1.57% |
| 2022 | 4.21 Million USD | -20.88% |
| 2021 | 5.32 Million USD | -52.95% |
| 2020 | 11.31 Million USD | 568.74% |
| 2019 | 1.69 Million USD | -19.02% |
| 2018 | 2.08 Million USD | -4.69% |
| 2017 | 2.19 Million USD | 51.27% |
| 2016 | 1.44 Million USD | 14.87% |
| 2015 | 1.26 Million USD | 70.84% |
| 2014 | 738.45 Thousand USD | 1199.57% |
| 2013 | 56.82 Thousand USD | -57.22% |
| 2012 | 132.82 Thousand USD | 83.7% |
| 2011 | 72.3 Thousand USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.72 Million USD | -5.73% |
| 2024 Q1 | 3.95 Million USD | -4.63% |
| 2023 FY | 4.14 Million USD | -1.57% |
| 2023 Q2 | 4.24 Million USD | 5.03% |
| 2023 Q4 | 4.14 Million USD | 2.52% |
| 2023 Q3 | 4.04 Million USD | -4.77% |
| 2023 Q1 | 4.04 Million USD | -4.01% |
| 2022 Q3 | 4.47 Million USD | -0.94% |
| 2022 FY | 4.21 Million USD | -20.88% |
| 2022 Q4 | 4.21 Million USD | -5.95% |
| 2022 Q1 | 5.06 Million USD | -4.86% |
| 2022 Q2 | 4.52 Million USD | -10.73% |
| 2021 Q3 | 14.24 Million USD | 37.62% |
| 2021 Q4 | 5.32 Million USD | -62.64% |
| 2021 Q1 | 11.26 Million USD | -0.41% |
| 2021 Q2 | 10.35 Million USD | -8.13% |
| 2021 FY | 5.32 Million USD | -52.95% |
| 2020 FY | 11.31 Million USD | 568.74% |
| 2020 Q1 | 10.91 Million USD | 545.12% |
| 2020 Q2 | 11.07 Million USD | 1.44% |
| 2020 Q3 | 12.12 Million USD | 9.55% |
| 2020 Q4 | 11.31 Million USD | -6.72% |
| 2019 Q4 | 1.69 Million USD | -28.81% |
| 2019 FY | 1.69 Million USD | -19.02% |
| 2019 Q2 | 2.88 Million USD | -4.51% |
| 2019 Q1 | 3.01 Million USD | 44.45% |
| 2019 Q3 | 2.37 Million USD | -17.53% |
| 2018 Q3 | 791.69 Thousand USD | 15.36% |
| 2018 FY | 2.08 Million USD | -4.69% |
| 2018 Q4 | 2.08 Million USD | 163.9% |
| 2018 Q2 | 686.29 Thousand USD | -17.75% |
| 2018 Q1 | 834.38 Thousand USD | -61.94% |
| 2017 FY | 2.19 Million USD | 51.27% |
| 2017 Q2 | 4.41 Million USD | 435.15% |
| 2017 Q3 | 3.32 Million USD | -24.73% |
| 2017 Q4 | 2.19 Million USD | -34.01% |
| 2017 Q1 | 824.76 Thousand USD | -43.09% |
| 2016 Q4 | 1.44 Million USD | 17.79% |
| 2016 Q2 | 481.23 Thousand USD | -26.52% |
| 2016 Q1 | 654.89 Thousand USD | -48.09% |
| 2016 FY | 1.44 Million USD | 14.87% |
| 2016 Q3 | 1.23 Million USD | 155.66% |
| 2015 Q3 | 1.82 Million USD | -41.22% |
| 2015 Q4 | 1.26 Million USD | -30.87% |
| 2015 Q2 | 3.1 Million USD | 1217.92% |
| 2015 Q1 | 235.59 Thousand USD | -68.1% |
| 2015 FY | 1.26 Million USD | 70.84% |
| 2014 Q1 | 52.1 Thousand USD | -8.31% |
| 2014 Q4 | 738.45 Thousand USD | -30.48% |
| 2014 Q3 | 1.06 Million USD | 21854.92% |
| 2014 Q2 | 4838.00 USD | -90.71% |
| 2014 FY | 738.45 Thousand USD | 1199.57% |
| 2013 FY | 56.82 Thousand USD | -57.22% |
| 2013 Q4 | 56.82 Thousand USD | -37.51% |
| 2013 Q3 | 90.93 Thousand USD | -5.62% |
| 2013 Q1 | 125.62 Thousand USD | -5.42% |
| 2013 Q2 | 96.34 Thousand USD | -23.31% |
| 2012 Q4 | 132.82 Thousand USD | 95.55% |
| 2012 Q3 | 67.92 Thousand USD | 16.56% |
| 2012 FY | 132.82 Thousand USD | 83.7% |
| 2012 Q1 | 87.05 Thousand USD | 20.4% |
| 2012 Q2 | 58.27 Thousand USD | -33.06% |
| 2011 Q4 | 72.3 Thousand USD | 452.46% |
| 2011 Q3 | 13.08 Thousand USD | 0.0% |
| 2011 FY | 72.3 Thousand USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -179381.472% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -111.727% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 60.716% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -650.928% |
| Rebus Holdings, Inc. | 5000.00 USD | -82820.44% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 96.816% |
| Qrons Inc. | 420.00 USD | -987048.095% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -437.994% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 85.163% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -762.753% |
| Skye Bioscience, Inc. | 11.94 Million USD | 65.277% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 89.327% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 42.574% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -5330.0% |
| SQZ Biotechnologies Company | 107.18 Million USD | 96.132% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -189.52% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -5629.319% |
| Mesoblast Limited | 667.9 Million USD | 99.379% |
| Marizyme, Inc. | 22.01 Million USD | 81.167% |
| Genus plc | 1.02 Billion USD | 99.597% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -205.224% |
| Pharming Group N.V. | 462.85 Million USD | 99.104% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -25.144% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -730.801% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -561.248% |
| ContraFect Corporation | 20.67 Million USD | 79.951% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -962.086% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -984.843% |
| IMV Inc. | 31.33 Million USD | 86.768% |
| MultiCell Technologies, Inc. | 126.22 USD | -3284658.358% |
| ONE Bio Corp. | 70.08 Million USD | 94.084% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -341.212% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 96.774% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -860.363% |
| Q BioMed Inc. | 3.51 Million USD | -17.935% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 88.214% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1486.83% |
| Biomind Labs Inc. | 73.81 Thousand USD | -5516.47% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.071% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -186.161% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 86.187% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -50.966% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -503.07% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -59.267% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3908.064% |
| Alpha Cognition Inc. | 2.45 Million USD | -69.076% |
| HST Global, Inc. | 1526.00 USD | -271592.136% |
| CSL Limited | 38.02 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -319.652% |
| Halberd Corporation | 10.13 Thousand USD | -40824.114% |
| Enzolytics Inc. | 361.7 Million USD | 98.854% |
| Agentix Corp. | 261.39 Thousand USD | -1486.132% |
| Resverlogix Corp. | 8.11 Million USD | 48.909% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -120.782% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.909% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 91.308% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -548.164% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -18099.473% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 53.671% |
| AVAX Technologies, Inc. | 7.37 Million USD | 43.799% |
| Zenith Capital Corp. | 7410.00 USD | -55851.714% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.878% |
| Ember Therapeutics, Inc. | 184.00 USD | -2253172.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1188.361% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1486.302% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -346.788% |
| Kadimastem Ltd | 2.3 Million USD | -79.943% |
| Helix BioMedix, Inc. | 3.02 Million USD | -37.055% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 92.133% |
| BioStem Technologies, Inc. | 14.56 Million USD | 71.525% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -7161.747% |
| LadRx Corporation | 2.3 Million USD | -79.646% |
| Cell Source, Inc. | 195.17 Thousand USD | -2024.302% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1072.461% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1072.461% |
| NovAccess Global Inc. | 62.24 Thousand USD | -6560.49% |
| Affymax, Inc. | 7.44 Million USD | 44.296% |
| Itoco Inc. | 1.4 Million USD | -196.129% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -4234.259% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3811.342% |
| Mobile Lads Corp. | 52.00 USD | -7973019.231% |
| CytoDyn Inc. | 11.13 Million USD | 62.769% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2799.884% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -23088.043% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -975.573% |
| SYBLEU INC | 330.46 Thousand USD | -1154.591% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -912.652% |
| International Stem Cell Corporation | 5.39 Million USD | 23.079% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2912.266% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 72.363% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 74.992% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -5148.129% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -379.488% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 44.845% |
| Neutra Corp. | 2851.00 USD | -145323.43% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 87.206% |
| PureTech Health plc | 693.97 Million USD | 99.403% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 48.631% |
| IXICO plc | 15.84 Million USD | 73.832% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 49.939% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.987% |
| CSL Limited | 38.02 Billion USD | 99.989% |
| Cellectis S.A. | 333.99 Million USD | 98.759% |